Autres langues Septerna, Inc.

Actions

SEPN

US81734D1046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
37,77 ^USD	-0,94%		-2,38%	+35,47%

25/08	Septerna, Inc. annonce la nomination de Rajiv Patni au poste de Chief Medical Officer	CI
10/08	Septerna : réduction de la perte nette et hausse du chiffre d'affaires au deuxième trimestre	MT

Autres langues

10/09	Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/09	Septerna to Participate in Upcoming Investor Conferences
25/08	Septerna, Inc. Announces Appointment of Rajiv Patni as Chief Medical Officer
25/08	Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
10/08	Septerna Q2 Loss Narrows, Revenue Rises
10/08	Earnings Flash (SEPN) Septerna Posts Q2 Loss Per Share $0.29, vs. FactSet Est of $0.43 Loss
10/08	Earnings Flash (SEPN) Septerna, Inc. Reports Q2 Revenue $26.7M, vs. FactSet Est of $19.2M
10/08	Septerna, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
29/06	Septerna, Inc.(NasdaqGM:SEPN) added to Russell 2000 Growth Benchmark
29/06	Septerna, Inc.(NasdaqGM:SEPN) added to Russell 3000E Growth Benchmark
29/06	Septerna, Inc.(NasdaqGM:SEPN) added to Russell 3000 Growth Benchmark
29/06	Septerna, Inc.(NasdaqGM:SEPN) added to Russell Small Cap Comp Growth Benchmark
29/06	Septerna, Inc.(NasdaqGM:SEPN) added to Russell 2500 Growth Benchmark
08/06	Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
11/05	Septerna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Earnings Flash (SEPN) Septerna, Inc. Reports Q1 Revenue $26.5M, vs. FactSet Est of $17.0M
11/05	Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
05/05	Septerna to Present at Bank of America Securities Health Care Conference
05/05	Septerna to Present at Bank of America Securities Health Care Conference
13/04	Septerna Doses First Participants in Phase 1 Clinical Trial For Hypoparathyroidism Drug
13/04	Septerna, Inc. Announces Initiation of Phase 1 Trial for Oral PTH1R Agonist SEP-479 in Hypoparathyroidism
13/04	Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
09/03	Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24
09/03	Septerna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025